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Abstract
Background: Knowledge of HIV status can be important in reducing the risk of HIV exposure. In a European sample of
men-who-have-sex-with-men (MSM), we aimed to identify factors associated with HIV serostatus disclosure to the most
recent anal intercourse (AI) partner. We also aimed to describe the impact of HIV serostatus disclosure on HIV exposure
risks.
Methods: During 2013 and 2014, 4901 participants were recruited for the bio-behavioural Sialon-II study in 13 European
cities. Behavioural data were collected with a self-administered paper questionnaire. Biological specimens were tested for
HIV antibodies. Factors associated with HIV serostatus disclosure with the most recent AI partner were examined using
bivariate and multilevel multivariate logistic regression analysis. We also describe the role of serostatus disclosure for HIV
exposure of the most recent AI partner.
Results: Thirty-five percent (n = 1450) of the study participants reported mutual serostatus disclosure with their most
recent AI partner or disclosed having HIV to their partner. Most of these disclosures occurred between steady partners
(74%, n = 1077). In addition to the type of partner and HIV diagnosis status, other factors positively associated with HIV
serostatus disclosure in the multilevel multivariate logistic regression model were recent testing, no condom use, and
outness regarding sexual orientation. Disclosure rates were lowest in three south-eastern European cities.
Following condom use (51%, n = 2099), HIV serostatus disclosure (20%, n = 807) was the second most common
prevention approach with the most recent AI partner, usually resulting in serosorting. A potential HIV exposure risk for the
partner was reported by 26% (111/432) of HIV antibody positive study participants. In 18% (20/111) of exposure episodes,
an incorrect HIV serostatus was unknowingly communicated. Partner exposures were equally distributed between steady
and non-steady partners.
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Conclusions: The probability of HIV exposure through condomless AI is substantially lower after serostatus disclosure
compared to non-disclosure. Incorrect knowledge of one’s HIV status contributes to a large proportion of HIV exposures
amongst European MSM. Maintaining or improving condom use for anal intercourse with non-steady partners, frequent
testing to update HIV serostatus awareness, and increased serostatus disclosure particularly between steady partners are
confirmed as key aspects for reducing HIV exposures amongst European MSM.
Keywords: Men who have sex with men, Bio-behavioural survey, HIV serostatus disclosure, HIV exposure
Background
Human Immunodeficiency Virus (HIV)-testing is pro-
moted amongst people at increased risk of HIV infection
mainly to enable early diagnosis and treatment for those
found HIV positive, but also to support HIV/AIDS liter-
acy and ultimately behaviour change [1]. The impact of
HIV test results on sexual behaviour and transmission
risk behaviour has more frequently been analysed for
people diagnosed with an HIV infection than for people
receiving a negative HIV test result [2, 3]. Findings re-
garding the association between serostatus disclosure
and sexual risks amongst MSM have been inconsistent
[4]: disclosure of a positive HIV serostatus is often asso-
ciated with a reduced risk for HIV transmission either
because no anal intercourse (AI) takes place, or through
subsequent condom use if serodiscordant, or through
condomless anal intercourse (CLAI) if seroconcordant
(condom serosorting). The risk for other sexually trans-
mitted infections (STIs) however, may increase if HIV
serostatus disclosure leads to CLAI [5]. The conse-
quences of seronegative status disclosure on HIV trans-
mission risk remain less clear [6–8].
A substantial body of literature on the enabling and hin-
dering factors for HIV status disclosure between MSM has
been published, identifying the following factors associated
with disclosure of HIV serostatus: disclosure is more likely
between steady partners compared to non-steady partners;
and for non-steady partners, disclosure depends on the set-
ting where the partners have met. HIV positive status dis-
closure is negatively associated with perceived HIV-related
stigma, depressive symptoms, and increasing age (if older
than 50 years) [4, 9–18].
A negative HIV test result is often used to guide deci-
sions on condom use for AI,particularly in the context of
mutual HIV serostatus disclosure with steady and, to a
lesser degree, with non-steady partners [19]. Disclosure of
the last HIV test result can be inaccurate if HIV serocon-
version occurred after the test result was received, which
may then result in unintended HIV exposure of assumed
seroconcordant HIV negative partners. In this present
study, we term this “failed serosorting”. The frequency with
which failed serosorting occurs depends on the frequency
and type of partners for CLAI after having received a nega-
tive HIV antibody test result, testing frequency, and the
reliability of HIV serostatus information communicated by
sexual partners. Serostatus disclosure can be compromised
by people disclosing a negative HIV status despite having
never been tested; a phenomenon repeatedly observed but
rarely analysed and reported in MSM surveys [19, 20].
A major advantage of bio-behavioural surveys compared
to behavioural surveys is the possibility to analyse the
accuracy of assumed HIV serostatus. Furthermore, they
also allow the effects of condom use decisions following
serostatus disclosure on HIV exposure risks to be explored,
particularly when analysing serostatus disclosure to partici-
pants’ last AI partner(s).
There are two objectives we aim to address with the
present paper. First, we aim to describe the frequency of
HIV serostatus disclosure and to identify factors associated
with HIV serostatus disclosure to the most recent AI part-
ner in a multi-city European MSM sample. Second, based
on self-reported behaviours, we aim to examine the effects
of serostatus disclosure in relation to other risk manage-
ment tactics on HIV exposure risks for sexual partners of
study participants with HIV antibodies during the most
recent AI episode in the study population.
Methods
Study procedures
Study participants were recruited to the European bio-
behavioural Sialon-II study using Time-Location Sam-
pling (TLS) in nine cities (Barcelona, Brighton, Brussels,
Hamburg, Lisbon, Ljubljana, Sofia, Stockholm, and
Warsaw) and Respondent-Driven Sampling (RDS) in
four cities (Bratislava, Bucharest, Verona, and Vilnius).-
Participants were eligible for enrolment if they were:
males aged 18 years or older, and; had had sex with at
least one male partner in the previous 12 months, and;
gave their consent to all study procedures including filling
out an anonymous self-administered questionnaire and
providing a biological sample for testing. Recruitment
methods, study procedures, questions asked, and sample
collection and testing have been published elsewhere [21].
The study protocol was approved by the World Health
Organization (WHO) Research Project Review Panel
(RP2) and the WHO Research Ethics Review Committee
(WHO-ERC), and by ethics review committees in all par-
ticipating countries.
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In TLS cities, participants were recruited during 2013,
whilst in RDS cities recruitment started in 2013 and fin-
ished in 2014.
Measures
In this article, we focus on participant characteristics,
societal attitudes experienced by gay and bisexual men,
as well as relationships and behaviours with the most
recent AI partner. The timing of the most recent AI
event was not elicited. To measure the outcome ‘serosta-
tus disclosure to the most recent AI partners’ a variable
was constructed based on respective questions on HIV
serostatus communication with the last AI partner.
There were two questions: 1) What did you tell your last
AI partner about your HIV serostatus? and 2) What did
you think about the HIV serostatus of your last AI
partner before you had sex? The response options for 1)
being: I told him I don’t know; I am HIV-negative; I am
HIV-positive; I said nothing; I don’t remember; I refuse
to answer. The response options for 2) being: I assumed
he is HIV-negative/positive; I knew he is HIV-negative/
positive; I knew he didn’t know his status; I didn’t think
about; I don’t remember; I refuse to answer. The con-
structed variable distinguishes between successful seros-
tatus disclosure (i.e. a communication that establishes
HIV serostatus concordance or discordance, including
unilateral HIV infection disclosure), and unsuccessful
serostatus disclosure (i.e. a communication where either
none or only one of the involved partners disclosed his
serostatus, with the exception of unilateral HIV infection
disclosure, see above). Respondents indicated whether
the most recent AI partner was a steady or non-steady
partner (steady included ‘boyfriends’ and ‘husbands’, and
excluded ‘sex buddies’; see Additional file 1 ‘Study
questionnaire’).
Mutual disclosure was assumed if the respondent had
both disclosed his status to his partner and indicated
knowing the status of his partner prior to engaging in
AI. If AI was reported with a steady partner, we cannot
assume that the most recent AI was the first occasion to
communicate about HIV status; therefore, the definition
for serostatus disclosure with steady partners was broad-
ened to include those who indicated knowledge of their
partners’ HIV serostatus and reported a concordant last
HIV test result, but did not explicitly confirm that they
had disclosed their serostatus to their steady partner at
this most recent AI episode.
Those reporting more than one partner during the most
recent AI were included, but criteria for categorisation of
disclosures were stricter because the questionnaire was
not designed to assess behaviours with multiple partners
(see Additional file 2).
The second outcome is a purely quantitative description
of risk management tactics used with the participant’s
most recent AI partner, including the assessment whether
the partners of those who are HIV antibody positive have
potentially been exposed to HIV. Here, the self-reported
risk management tactics which are serostatus-dependent
are contrasted with the HIV antibody test result of a self-
collected oral fluid specimen (collected in TLS cities) or a
blood specimen (collected in RDS cities). The test result
could confirm or contradict the assumed HIV status, i.e.
self-reported serostatus was qualified as either accurate or
inaccurate. A hierarchy of six risk management tactics (in-
cluding those not requiring communication, those requiring
communication, and a lack of discernible risk management)
were defined with the following order: 1) condom use; 2)
treatment with anti-retroviral therapy (ART) to maintain an
undetectable viral load; 3) true serostatus concordance (as-
suming that reported serostatus of the partner was correct);
4) true serostatus discordance (i.e. both partners aware of
HIV discordance and not reporting condom use or
undetectable viral load); 5) falsely assumed serostatus
concordance (i.e. self-report of a negative HIV test result
and disclosing this result to their most recent AI partner
although HIV antibodies were detected in the specimen
provided for testing on the day of the study participation;
alternatively, this could also be due to having been infected
by this most recent AI partner, in which case this partner
and not the respondent falsely assumed serostatus concord-
ance; 6) none of the risk reduction tactics described above
whilst reporting CLAI with HIV antibodies detected in the
specimen (e.g. a participant who reported CLAI with his
most recent non-steady AI partner but without communi-
cating his HIV status). If a participant was HIV-positive, the
last three risk management tactics were assumed to have
potentially exposed their most recent AI partner to HIV,
and were stratified by type of partner into men disclosing
correctly their actual HIV status, men disclosing (unknow-
ingly) an incorrect HIV status, men who did not communi-
cate with their partner about their HIV status or who did
not provide this information, and men for whom we were
unable to determine their HIV status awareness.
Statistical analysis
For the first outcome variable, factors associated with suc-
cessful HIV serostatus disclosure with the last AI partner
were identified using a two-level multilevel logistic regres-
sion model (MLM) with individuals nested within city and
a random intercept for city. The random component
accounts for locational clustering. To explore potential
explanatory variables for entry into the models, bivariate
analyses were used to assess the associations between indi-
vidual variables and successful HIV serostatus disclosure.
Variables included in the MLM model were those with a
statistically significant association (p-value <0.05) in the
bivariate analysis. Model selection for the MLM used the
forward approach and variables were retained if p-value
Marcus et al. BMC Infectious Diseases  (2017) 17:730 Page 3 of 17
<0.10. As each variable was added, the new model was
compared to the nested model using a likelihood ratio test.
Significance was determined by p < 0.05.
The final MLM estimated the odds ratio (OR) and the
corresponding 95% confidence interval (95% CI) for factors
statistically significantly associated with successful serostatus
disclosure. Stata® Version 14 was used for all analyses.
The following explanatory variables were analysed: age
(categorised in 10-year age groups), migration status
(whether living in a country other than the country of
birth), education (categorised as secondary or lower, high
school diploma to post-secondary, university or higher),
frequency of visiting gay venues with the possibility of
sex-on-premises in the last 3 months (no, low or high),
outness (the degree to which people are open about
their sexual attraction with family members, friends and
co-workers, categorised as open to nobody or few, to
less than half, to more than half, to all or almost all),
type of partner during the most recent AI episode
(steady, non-steady), condom use during the most recent
AI episode (condom use, no condom use), HIV status
awareness, (self-reported) viral load if HIV positive (de-
tectable, undetectable), recency of the last HIV test (last
12 months, >12 months ago, or never tested), sexual role
during the most recent AI episode (receptive, insertive,
both), and substance use in the context of the most re-
cent AI episode (no substance, one-to-two substances,
more than two substances). We also hypothesised the
following: 1) that a recent negative HIV antibody test
result, as well as a recent viral load test below the detec-
tion limit, would both increase the intention to disclose
these results to a sexual partner and; 2) not having been
tested for HIV antibodies and being diagnosed with HIV
and having a detectable viral load would decrease the
likelihood of disclosing this to potential sexual partners.
Thus we constructed a variable distinguishing between
men reporting a recent (<12 months) negative HIV
antibody test or a positive HIV antibody test with a
recent viral load below the limit of detection, and the
other reported possibilities, such as no history of previ-
ous HIV testing or a positive HIV antibody test without
reporting a viral load below the limit of detection.
Perceived stigma towards gay/bisexual people was
assessed using a 5-point Likert scale ranging from 1
(very negative) to 5 (very positive) regarding respon-
dents’ perceptions of homophobia across three domains:
1) work/school; 2) parents, and; 3) friends/acquaintances
(Cronbach’s alpha = 0.73). The points from the three di-
mensions were added for a score: 1–7.5 points were de-
fined as “negative attitudes”, 8–10.5 points as “neutral
attitudes”, and 11–15 points as “positive attitudes”. To
account for missing values the Predictive Mean Match-
ing (PMM) was used. Three variables related to the per-
ceived attitude towards gay and bisexual individuals in
social contexts were imputed: the perceived attitude to-
wards gay and bisexual men at school/work (missing
n = 182/4091), the perceived attitude from parents or
family members (missing n = 301/4091), and the per-
ceived attitude from friends or acquaintances (missing
n = 236/4091). The procedure used as predictors city,
education and outness. PMM as a semi-parametric
imputation approach allows imputed values to be more
plausible when the normality assumption is violated.
To summarise HIV risk management tactics and HIV ex-
posure risk, descriptive statistics (counts and proportions)
where used. HIV exposure risk was analysed exclusively for
the last AI partners of study participants with a biological
specimen in which HIV antibodies had been detected. Par-
ticipants who themselves did not have HIV and reported a
last AI partner with HIV were not considered because in-
formation on treatment and viral load communication with
the last AI partner was not collected.
No sampling weights were applied during statistical
analysis because we wanted to model the relationship
between explanatory variables and the outcome ‘serosta-
tus disclosure to the last AI partner’ and did not intend
to generalise the result to the specific study populations
in the different cities.
Results
Study sample
We recruited 4901 participants in the 13 study cities, with
3596 participants from the 9 TLS cities, and 1305 from the
4 RDS cities. Median age was 32 years (IQR: 26–41 years),
12% (n = 456) of the participants were immigrants (born
abroad and living in the study country), 5% (n = 213) were
visitors (born abroad and visiting in the study country).
HIV antibodies were detected in the biological specimens
of 497 study participants. A previous HIV diagnosis was re-
ported by 234, a previous negative HIV test result or no
previous HIV test were reported by 163, and for 100 study
participants it was not possible to determine their HIV
status awareness due to missing responses. A detailed de-
scription of the study sample has been published in the
study report [22].
Missing values
The proportion of missing values ranged from 0.1% (n = 5)
for age to 26% (n = 1292) for condom use with the most
recent AI partner. Data were missing on measured HIV
antibody status or self-reported serostatus knowledge for
7% (n = 320) of respondents. For most of the items ana-
lysed in this paper, responses were available from approxi-
mately 4000 participants (range: 3609–4110; see Table 1).
The final MLM which included the condom use variable
was based on 3219 observations.
Marcus et al. BMC Infectious Diseases  (2017) 17:730 Page 4 of 17
Table 1 Association of demographic, behavioural, psychosocial and biological factors with HIV serostatus disclosure to the most
recent anal intercourse partner amongst MSM in 13 European cities, Sialon-II bio-behavioural survey, 2013–2014
Proportion with HIV
serostatus disclosure
at the last AI
Odds Ratio 95% Confidence Interval p-value^
Age group [years] 18–24 31.6% 0.82 0.68 0.97 0.024
25–34 36.1% ref.
35–44 39.5% 1.15 0.98 1.36 0.092
45–54 32.9% 0.87 0.70 1.07 0.195
55+ 31.3% 0.80 0.59 1.10 0.169
Total 35.3% 0.0040
Education secondary school
or lower
28.1% 0.66 0.49 0.90 0.01
high school diploma
or post-secondary
33.1% 0.84 0.73 0.96 0.01
university studies
or higher
37.1% ref.
Total 35.1% 0.0035
Migration status native 34.1% ref.
migrant 41.0% 1.34 1.13 1.59 <0.001
Total 35.2%
City Hamburg 35.9% ref.
Barcelona 37.0% 1.05 0.77 1.43
Bratislava (RDS) 26.4% 0.64 0.46 0.89
Brighton 46.9% 1.57 1.15 2.15
Brussels 43.4% 1.37 1.00 1.87
Bucharest (RDS) 22.8% 0.53 0.34 0.82
Lisbon 37.7% 1.08 0.80 1.47
Ljubljana 42.1% 1.30 0.95 1.77
Sofia 29.6% 0.75 0.55 1.02
Stockholm 39.0% 1.14 0.81 1.60
Verona (RDS) 29.6% 0.75 0.55 1.03
Vilnius (RDS) 33.4% 0.90 0.65 1.24
Warsaw 32.2% 0.85 0.62 1.16
Total 35.3%
Frequency of gay sex venue
attendance in recent 3 months
no 34.7% ref.
low (1–3 times) 36.1% 1.06 0.90 1.24 0.49
high (>3 times) 34.6% 0.99 0.84 1.18 0.95
Total 35.3% 0.67
Perceived gay stigma experienced positive
attitudes (score points
11–15)
40.7% ref.
experienced neutral
attitudes (score points
8–10.5)
32.7% 0.70 0.61 0.81 <0.001
experienced negative
attitudes (score points
1–7.5)
26.4% 0.53 0.43 0.64 <0.001
Total 35.3% <0.001
Outness towards family, friends
and co-workers
nobody/few 27.1% ref.
less than half 31.8% 1.25 1.01 1.56 0.04
more than half 35.8% 1.50 1.23 1.83 <0.001
all/almost all 41.8% 1.93 1.64 2.28 <0.001
Total 35.3% <0.001
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Factors associated with HIV serostatus disclosure
Of those who answered the respective questions, success-
ful serostatus disclosure to the most recent AI partner was
reported by more than one third of study participants
(35%, 1451/4110; see Table 1). HIV serostatus disclosure
at the last AI was more common if the partner was a
steady partner (54%) compared to a non-steady partner
(17%); it was highest in the age group 35–44 years (40%)
and higher amongst migrants (41%) than non-migrants
(34%). Men with higher education were more likely to
Table 1 Association of demographic, behavioural, psychosocial and biological factors with HIV serostatus disclosure to the most
recent anal intercourse partner amongst MSM in 13 European cities, Sialon-II bio-behavioural survey, 2013–2014 (Continued)
Proportion with HIV
serostatus disclosure
at the last AI
Odds Ratio 95% Confidence Interval p-value^
Number of CLAI partners in
most recent 6 months
no partner 28.9% ref.
1 partner 48.4% 2.31 1.96 2.72 <0.001
2–5 partners 33.6% 1.25 1.05 1.48 0.01
6–10 partners 26.5% 0.89 0.64 1.24 0.49
>10 partners 32.4% 1.18 0.82 1.70 0.37
Total 35.6% <0.001
Type of partner during most
recent AI
steady 54.1% ref.
non-steady 17.2% 0.18 0.15 0.20 <0.001
more than one 21.0% 0.23 0.16 0.31 <0.001
Total 35.3% <0.001
Condom use during most
recent AI
condom use during
last AI
26.6% ref.
no condom use 47.8% 2.52 2.19 2.91 <0.001
Total 35.6% <0.001
HIV test during last 12 months HIV test last 12 months 40.8% ref.
never tested or tested
>12 months ago
26.9% 0.53 0.47 0.61 <0.001
Total 34.9% <0.001
Negative HIV test result during
last 12 months
no negative test resultb 27.4% ref.
negative antibody test 40.6% 1.81 1.58 2.06 <0.001
negative viral load test 55.3% 3.28 2.36 4.56 <0.001
Total 35.3% <0.001
Most recent viral load measurementa detectable viral load 60.6% ref.
undetectable viral load 55.7% 0.82 0.38 1.75 0.60
respondent did not know 28.3% 0.26 0.12 0.54 <0.001
Total 39.8% <0.001
Sexual role during most recent AI insertive 35.3% ref.
receptive 32.8% 0.89 0.76 1.05 0.17
both 39.1% 1.17 1.00 1.38 0.05
Total 35.5% 0.005
Number of substances used during
most recent AI
no substances 39.7% ref.
1–2 substances 31.8% 0.71 0.62 0.81 <0.001
> 2 substances 32.1% 0.72 0.56 0.91 0.01
Total 35.3% <0.001
HIV status awareness newly diagnosed 22.5% ref.
negative 35.0% 1.86 1.24 2.79 <0.001
already known 56.4% 4.47 2.76 7.23 <0.001
Total 35.8% <0.001
RDS Respondent Driven Sampling, AI anal intercourse, CLAI condomless anal intercourse, OR Odds Ratio. OR <1.0 indicates lower odds for disclosure, bold
indicates ORs with a p-value <0.05
^The p-value from Wald test for categorical variables is reported on the variable’s Total row
aa previous HIV diagnosis was reported by 234 study participants; only these could report on the last viral load measurement
b no negative test result includes men not tested for HIV antibodies, and HIV antibody positive men with detectable viral load
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disclose their serostatus than those with secondary or
lower levels. Compared with study participants who were
out about their sexual orientation to ‘nobody or only a few
people’, increasing proportions of those who were out to
‘less than half ’, ‘more than half ’, or ‘almost all or all’ of the
people they knew disclosed their serostatus. Serostatus
disclosure varied considerably between study cities with a
North-West (high) to South-East (low) gradient. There
were no differences regarding serostatus disclosure be-
tween respondents frequently visiting sex-on-premises
venues in the last 3 months and gay venues without this
option. It was more common amongst study participants
reporting an HIV test in the last 12 months (41%) than
amongst men who tested longer than 12 months ago or
never (27%); it was also more common amongst men
aware of having HIV (56%) than amongst men having re-
ceived a negative HIV test result (35%). Serostatus disclos-
ure was lowest amongst men reporting a last negative test
result but testing positive for HIV antibodies in the speci-
men provided in the study (23%). Disclosure was most
common if the respondents reported only one CLAI part-
ner in the last 6 months, followed by the group with 2–5
CLAI partners. Compared to serostatus disclosure of men
who were insertive (35%) during the most recent AI epi-
sode, a larger proportion of men reporting both receptive
and insertive AI disclosed (39%), while serostatus disclos-
ure was less common amongst men reporting only being
receptive (33%). Likewise, serostatus disclosure was less
common amongst men reporting condom-protected AI
(27%) compared to CLAI (48%). The use of drugs in con-
nection with the most recent AI was negatively associated
with serostatus disclosure: participants reporting sub-
stance use during their last AI episode reported less seros-
tatus disclosure than those who reported no substance
use, but no dose-response effect (decreasing proportions
who disclosed with increasing number of drugs con-
sumed) was detected.
Table 2 shows the results of the final MLM to explore
factors associated with successful HIV serostatus disclos-
ure. Factors associated with increased successful serosta-
tus disclosure were: having a recent negative HIV
antibody test (OR = 2.69, 95% CI: 2.23, 3.23; p < 0.001),
being out to all/almost all family, friends and co-workers
(OR = 1.69, 95% CI: 1.32, 2.16; p < 0.001), already knowing
HIV status (OR = 6.47, 95% CI: 3.37, 12.45; p < 0.001) and
HIV risk management with the last AI partner other than
condom use (OR = 1.80, 95% CI: 1.51, 2.14; p < 0.001).
Factors associated with decreased success of serostatus
disclosure were: having a non-steady partner (OR = 0.16,
95% CI: 0.14, 0.20; p < 0.001), having more than one part-
ner (OR = 0.18, 95% CI: 0.12, 0.26; p < 0.001), having an
as yet undiagnosed HIV infection (OR = 0.51, 95% CI:
0.31,0.86; p = 0.01) and if gay stigma was perceived as
neutral (OR = 0.82, 95% CI: 0.68, 1.00; p = 0.04) or
negative (OR = 0.72, 95% CI: 0.54, 0.97; p = 0.03). The
likelihood ratio test comparing the final MLM with the
equivalent single-level model indicated that they did not
significantly differ (χ2(1) = 0.05, p = 0.41).
HIV risk management tactics in the study sample
We assessed the contribution of serostatus disclosure
and erroneous serostatus disclosure to HIV exposure
risks. For the definition of the risk management tactics
we choose the perspective of the respondents, who may
be unaware whether the serostatus they disclose is cor-
rect or not. They will usually know (1) whether condoms
were used and (2) their HIV status if they have been di-
agnosed with HIV, and whether they take antiretroviral
treatment.
Slightly more than half of the self-reported most re-
cent AI episodes between study participants and their
sex partners were protected by condom use and/or treat-
ment (53% after exclusion of missing data; see Table 3);
27 % of participants reported CLAI without explicit ser-
ostatus disclosure, and 20% reported AI episodes where
HIV-positive or HIV-negative seroconcordance had been
established by mutual disclosure or HIV infection had
been unilaterally disclosed.
Amongst the 27% (n = 1107) of participants who did
not report serostatus disclosure, almost half (48%) re-
ported assuming seroconcordance with their most recent
AI partner. Stratified by partner type, seroconcordance
was assumed by 53% of respondents reporting CLAI
without explicit serostatus disclosure with a steady part-
ner, by 46% of respondents reporting CLAI with a non-
steady partner, and by 33% of respondents reporting
CLAI with more than one partner (see Table 3).
Two percent of AI events (n = 92) were between partici-
pants living with HIV and reporting an undetectable viral
load due to ART and partners not known to have HIV.
Fourteen percent of all participants (677/4901) had to
be excluded from this analysis due to missing informa-
tion on the most recent AI or missing information on
the type of partner(s), and another 2% (n = 99) due to
an invalid biological sample not allowing for HIV seros-
tatus determination (see Table 3).
In our sample, we were unable to identify a modifying
impact of strategic positioning (choosing an insertive or
receptive role during CLAI to minimise respective HIV
transmission risks) on HIV exposure risks. However, ap-
proximately one quarter of these recent AI episodes
could not be categorised due to missing information.
HIV risk management of participants identified as being HIV
antibody positive
Regarding the quantitative distribution of the most recent
AI episodes involving study participants identified as HIV
antibody positive in the study specimen, a proportion of
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13% (n = 65) could not be categorised due to missing in-
formation (see Table 3). This was due to missing answers
regarding condom use, treatment and last viral load, as
well as missing or incomplete information on serostatus
disclosure with their most recent AI partner.
From the 432 AI episodes that could be categorised,
51% (n = 221) were protected primarily by condom
use, 21% (n = 92) were rendered less infectious or
non-infectious for HIV due to antiretroviral treatment
of participants diagnosed with HIV. A considerable
Table 2 Multilevel logistic regression: factors associated with HIV serostatus disclosure to the most recent anal intercourse partner
amongst MSM in 13 European cities, Sialon-II bio-behavioural survey, 2013–2014
Odds Ratio 95% Confidence Interval p-Value
Type of partner during most recent AI <0.001
steady partner ref.
non-steady partner 0.16 0.14 0.20 <0.001
more than one partner 0.18 0.12 0.26 <0.001
Negative HIV test result during last 12
months
<0.001
no HIV test result ref.
negative antibody test 2.69 2.23 3.23 <0.001
negative viral load test 0.63 0.30 1.33 0.23
Outness towards family members, friends,
and co-workers
<0.001
none or few ref.
less than half 1.22 0.91 1.63 0.18
more than half 1.32 1.00 1.73 0.05
all/almost all 1.69 1.32 2.16 <0.001
HIV status awareness <0.001
not infected with HIV
(tested or untested)
ref.
newly diagnosed 0.51 0.31 0.86 0.01
already known 6.47 3.37 12.45 <0.001
Age group 0.0747
18–24 0.80 0.64 1.00 0.051
25–34 ref.
35–44 1.10 0.89 1.37 0.37
45–54 0.84 0.63 1.14 0.26
55+ 0.79 0.51 1.24 0.31
Perceived gay stigma 0.04
experienced positive
attitudes (score points
11–15)
ref.
experienced neutral
attitudes (score points
8–10.5)
0.82 0.68 1.00 0.04
experienced negative
attitudes (score points
1–7.5)
0.72 0.54 0.97 0.03
Condom use during most recent AI <0.001
condom use ref.
no condom use 1.80 1.51 2.14 <0.001
_cons 0.46 0.34 0.62 <0.001
city 0.003 0,00 23.22
Likelihood Ratio test vs. logistic regression: chibar2(1) = 0.05; Prob ≥ chibar2 = 0.4089
RDS = Respondent Driven Sampling; AI = anal intercourse; OR = Odds Ratio
OR <1.0 indicates lower odds for disclosure, bold indicates ORs with a p-value ≤0.05
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proportion of condom-protected episodes (34%; 75/221)
involved participants who also reported being treated with
ART and having an undetectable viral load. Categories 3, 4
and 5, resembling self-reported HIV serosorting or serosta-
tus disclosure, comprised 38 individuals (9%; see Table 3).
From the 184 study participants with laboratory evidence
of HIV infection who did not report condom use or treat-
ment as disclosure-independent HIV risk management dur-
ing their last AI, we were able to determine HIV serostatus
awareness for 119. For 65 (65/184 = 35%) the available data
was inconclusive as to their HIV serostatus awareness.
Thirty-nine of the 119 (33%) were aware of having HIV, 80
were unaware. From these 39, 8 (21%) reported an HIV-
concordant sexual partner at the last AI, and 10 (26%) re-
ported HIV status disclosure to their last AI partner, who
was not known to have HIV. According to the data we col-
lected, 21 participants aware of having HIV reported nei-
ther condom use, nor a viral load below detection limit, nor
HIV serostatus disclosure or HIV serosorting with their last
AI partner. Among the 111 evaluable AI episodes (119–8)
with potential HIV exposure of the partner and information
available on HIV serostatus awareness, disclosure, and type
of partner, the majority (80/111) was unaware of having
HIV. Most of these had not communicated about their ser-
ostatus with their most recent AI partner, yet 20 partici-
pants (20/111 = 18%) had unknowingly disclosed an
incorrect HIV status. In the 176 episodes of not otherwise
protected AI with probable risk of HIV exposures, we could
not identify any indications of the use of strategic position-
ing to minimize transmission risks.
HIV serostatus disclosure and HIV exposures
In the subgroup of the sample that reported HIV
serostatus disclosure as HIV risk management
(n = 827), unexpected HIV exposure through CLAI
occurred in 20 of 827 (2%) episodes, CLAI in the absence
of serostatus disclosure was however associated with HIV
exposure in 81 of 1107 (7%) respective episodes. An add-
itional 65 AI episodes of men with undiagnosed HIV in-
fection could not be categorised due to missing data (for a
more detailed disaggregation see Fig. 1).
As shown in Fig. 1, the different possible combinations
of knowledge of the partner(s) and serostatus disclosure
are key factors which determine the probability of being
exposed for partners of MSM who have HIV. Essentially,
the exposure risk increases with increasing “emotional
distance” of the partner(s) and with decreasing commu-
nication about HIV serostatus.
There were 96 CLAI episodes involving HIV exposure of
one partner. These were equally distributed amongst steady
and non-steady partners (48 with non-steady partners; see
Table 3). In 88 encounters, no (n = 70) or no correct
(n = 18) serostatus disclosure occurred. However, 45 of the
88 episodes were with steady partners where we cannot dis-
tinguish between those only holding assumptions about
their own and their partners’ HIV status, those having dis-
closed incorrectly at a previous occasion and those whose
serostatus might have changed after having previously been
correctly disclosed. In 8 episodes their positive HIV status
had been disclosed to the partner according to self-report by
HIV positive study participants. For 22 episodes data were
missing to classify the communication that had occurred.
Six of the 48 episodes of HIV exposure of a steady
partner involved respondents already diagnosed with
HIV, all other respondents erroneously believed to be
HIV negative (n = 23) or had unknown or inconclu-
sive HIV serostatus knowledge (n = 19).
Amongst the 48 episodes of HIV exposure of a
non-steady partner, 13 respondents were already diag-
nosed with HIV, 20 respondents erroneously believed
not to be infected, and 15 respondents had unknown
HIV serostatus knowledge.
Fig. 1 Proportion of potentially HIV-exposed partners during last anal intercourse by type of partner and HIV serostatus disclosure*, Sialon-II
bio-behavioural survey, 2013–2014. *excluded: potential exposures associated with disclosed HIV infection status
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Discussion
More than one third of the study participants who
answered all relevant questions and provided a valid speci-
men for HIV antibody testing reported mutual serostatus
disclosure or unilateral disclosure of HIV infection with
their most recent AI partner. Most of these disclosures oc-
curred between steady partners, but a moderate propor-
tion also occurred between non-steady partners. Apart
from the type of partner, HIV serostatus disclosure was
positively associated with the recency of a negative HIV-
antibody test result, a positive HIV status, outness regard-
ing sexual orientation, and the lack of condom use. Lack
of condom use could also be phrased differently as risk
management tactics other than condom use. There was a
negative association with perceived anti-gay stigma.
These findings are in line with previous studies analys-
ing factors associated with HIV serostatus disclosure [11,
13–15], and confirm that a higher level of intimacy and
trust facilitates serostatus disclosure, as well as the per-
ception that the information on HIV serostatus is rela-
tively recent. The findings also confirm that serostatus
disclosure is perceived as an alternative to condom use,
predominantly within steady partnerships. The positive
association with outness and the negative association
with perceived anti-gay stigma point both to the import-
ant role of the societal attitudes towards gay men and
the political and cultural environment towards homo-
sexuality for the ability of MSM to use preventive ser-
vices such as HIV testing and to use serostatus
knowledge to adopt serostatus-based preventive strat-
egies. Notably, all three cities with significantly worse
disclosure levels used RDS for recruitment. RDS was
preferentially used in cities where TLS deemed unfeas-
ible due to the lack of gay venues. Therefore confound-
ing between RDS use and other variables with potential
impact on HIV serostatus disclosure has to be assumed,
and it is possible that RDS sampled a different stratum
of MSM populations compared to TLS. MSM recruited
in gay venues might be more likely to be “out” or to per-
ceive a gay-friendly environment, compared to those re-
cruited through a network-based method such as RDS,
which is more likely to allow the enrolment of a more
hidden population of non-gay-identifying MSM [23].
Other factors which may explain the differences between
study cities and countries could be internalised homone-
gativity or structural stigma. We could not explore these
factors in our study, but internalised homonegativity has
been shown to be negatively associated with being ex-
posed to HIV/STI information for MSM, access to HIV
testing, access to STI testing, access to condoms, and lit-
tle or no experience of gay-related hostility, while struc-
tural stigma has been associated with unmet prevention
needs, not using testing services, and not discussing
one’s sexuality in testing services [24, 25]. It is also
conceivable that perceived anti-gay stigma may have an
impact on self-esteem and perceived self-efficacy for ini-
tiating serostatus communication [26].
Notably, the study participants with undiagnosed HIV
infection were significantly less likely to disclose their as-
sumed negative serostatus to their most recent AI partner.
The reasons for this finding are unclear and require fur-
ther research. It could be that these participants already
suspect that their assumed serostatus is no longer valid, or
it could be that the lack of comfort with serostatus dis-
closure with their partners and the subsequent assump-
tions about their partners’ serostatus are risk factors for
being exposed and possibly infected by HIV, or it could be
that non-disclosure is associated with other risk behav-
iours such as visiting gay sex venues which may be associ-
ated with increased risk for HIV exposure.
The lack of association between serostatus disclosure
and venues visited is likely due to a lack of precision of
the study’s measurement tool: respondents were asked
which type of venues they had visited in the last 3
months (e.g. disco, bar, sauna, sex club etc.) not the
venue where they had met their most recent AI partner.
Moreover, online dating and chat sites which represent
one of the most relevant venues for serostatus disclosure
[16, 17] were not queried at all.
There was a lack of association of serostatus dis-
closure with the frequency of visiting specific gay sex
venues such as gay saunas, bars with backrooms, or
sex parties in the last 3 months, but we were unable
to adequately assess the association between the set-
ting where the most recent AI partner was met and
HIV serostatus disclosure with this partner through
our questionnaire [17].
Besides condom use, which remains by far the most
common risk management tactic amongst our study par-
ticipants used by 51% of respondents indicating suffi-
cient details about their most recent AI episode,
serostatus disclosure, usually followed by condom sero-
sorting was the second most frequently used risk man-
agement strategy, mostly used with steady partners.
Eighteen percent had CLAI with an apparently serocon-
cordant partner, and 27% reported CLAI in the absence
of other discernible protective behaviours. This differs
slightly from the Amsterdam Cohort studies [27] where
consistent condom use was reported in 64% of cases,
CLAI in 25%, and CLAI with serosorting in 11% of the
2137 follow-up visits. Discrepancies with our findings
may be due to shifts in risk management over time (e.g.
decreasing condom use or increased use of serosorting),
different composition of study samples, and differences
in study design and measurement.
A decrease in condom use over time since 2005 amongst
MSM in larger US cities has recently been reported, using
cross-sectional survey data from the National HIV
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Behavioral Surveillance (NHBS) [28]. In this survey the au-
thors concluded that decreasing condom use trends were
not explained by increasing serosorting or ART.
A group of authors analysing routinely collected be-
haviour data from HIV testing sites in Seattle over the
period 2002–2013 reported that serosorting was increas-
ing concurrent with a decline in non-concordant CLAI,
and that consistent condom use remained “fairly con-
stant” [29]. However, the data reported by these authors
also supports the view that consistent condom use was
declining. Several other studies also suggest an increas-
ing use of serostatus disclosure for HIV risk manage-
ment amongst MSM [30–32].
In the Amsterdam Cohort studies, MSM who practiced
serosorting were less likely to newly acquire HIV infection
[adjusted incidence rate ratio (aIRR) = 0.46; 95% CI: 0.13–
1.59] than MSM who had CLAI without serosorting. A
very similar effect size with a 47% lower risk for serosorting
compared to non-concordant CLAI was reported in the
Seattle study. Both studies compare well with our findings
on HIV exposure rates. In our sample, serostatus disclos-
ure more than halved the HIV exposure risk compared to
non-disclosure, yet the exposure risk remained consider-
able. Whilst differences in seroconversion rates between
men practicing serosorting and men practicing CLAI with
no discernible protective behaviours in the Amsterdam
Cohort were not statistically significant, MSM who consist-
ently used condoms were less likely to seroconvert than
MSM who had CLAI (aIRR = 0.37; 95% CI: 0.18–0.77). In
the Seattle study, MSM who did not report CLAI had the
lowest HIV-test positivity rate when compared to serosort-
ing or non-concordant CLAI.
Analysing the role of serostatus disclosure and concord-
ance for risk reduction amongst the subset of participants
with HIV antibodies, establishing seroconcordance or HIV
infection disclosure was the primary risk management tac-
tic for 9% (38/432) of the AI episodes, yet an incorrect ser-
ostatus due to being unaware of an undiagnosed HIV
infection was disclosed in 20 evaluable episodes. Having
an undetectable viral load due to ART was the most im-
portant reason for reduced HIV exposure in this group.
Just 26% (111/432) of the reported AI episodes in the sam-
ple of participants with HIV antibody-positive study speci-
mens appeared to be associated with potential HIV
exposure of the partner, and in 2% the partner may have
been aware of this risk.
Limitations
Our findings come with several limitations. Whilst we
used TLS and RDS as recruitment strategies which rep-
resent the current main approaches to conduct bio-
behavioural surveys to reduce recruitment bias, the
study sample is not (nor was it intended to be) represen-
tative for the MSM population of the 13 study cities
[33]. Therefore we joined the data and considered it as a
convenience sample without applying separate sampling
weights for all analyses, nor adjusting for clustering ef-
fects. It should be mentioned that RDS was used prefer-
entially in cities where TLS was deemed unfeasible due
to the relative lack of gay venues as indicated by the for-
mative research. Therefore confounding between RDS
use and other variables with potential impact on HIV
serostatus disclosure has to be assumed, in addition to
RDS possibly sampling a different stratum of the city
population compared to TLS [23]. In addition, neither
the laboratory specimen analysis nor the questionnaire
were designed to pinpoint the moment of HIV transmis-
sion in HIV positive participants. It is therefore possible
that the last sexual experience participants reported co-
incided with the infection.
As in all studies with self-reported behaviours, data may
be affected by recall and social desirability bias, particu-
larly since sensitive behaviours like CLAI were explored.
The generalisability of our findings is further limited by
considerable non-response rates for several of the beha-
viours analysed. The distribution of risk management tac-
tics for AI episodes reported by HIV antibody-positive
respondents could substantially change if the episodes
with missing information could be re-categorised. How-
ever, since the proportions that could not be categorised
were very similar in the subgroups with and without HIV
antibodies, there is no indication for a significant HIV
status-related non-response bias. We may underestimate
serostatus disclosure for people with more than one part-
ner at the most recent AI episode, between steady part-
ners, and with non-steady partners with whom the
respondents have sex on a regular basis, because we asked
for serostatus disclosure only in the context of the most
recent AI and not for all prior serostatus disclosures.
Amongst the risk management tactics analysed, we can
only assess the failure rate of serostatus disclosure. We are
unable to assess failure rates for condom use and for pre-
ventive effects of ART on HIV exposure. Since we used
closed questions to categorise risk management tactics, it
may well be possible that respondents applied other indi-
vidual measures to reduce or modify HIV transmission
risks (e.g. withdrawal before ejaculation). Finally, exposure
is not the same as transmission. Additional factors such as
viral load, concomitant STIs, frequency of CLAI, and
number of AI partners can greatly modify the HIV-
exposure associated transmission risk, and these factors
are unlikely to be distributed evenly amongst men having
CLAI with steady and non-steady partners, and amongst
men aware and unaware of having HIV.
Conclusions
We found that CLAI after mutual serostatus disclosure is
associated with a substantially lower risk for HIV exposure
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than non-disclosure, not using condoms, and not having a
partner on effective ART, confirming previous findings
[34]. However, incorrect knowledge of the current HIV
status could contribute to a large proportion of the
current HIV exposures amongst European MSM, both in
steady and non-steady partnerships. Within steady part-
nerships, these exposures will only be preventable either
by maintaining consistent condom use or by achieving
more accurate serostatus knowledge within steady part-
nerships through (couple) testing at the onset of the part-
nership, followed by ‘negotiated safety’ agreements and a
testing frequency which is adapted to the frequency of
CLAI with concurrent non-steady partners. This will re-
quire easily accessible testing services, including HIV self-
testing with home tests or home collection testing
schemes. It is unlikely that HIV exposures within steady
partnerships due to incorrect serostatus disclosure can be
addressed by oral HIV chemoprophylaxis (pre-exposure
prophylaxis; PrEP) because people tend to feel safe with
their steady partners. On the contrary, exposures outside
steady partnerships, associated mostly with no HIV seros-
tatus disclosure, could be prevented by oral chemo-
prophylaxis, as well as by condom use and more frequent
and accurate HIV serostatus disclosure. Taking PrEP
would also be accompanied by more frequent HIV testing,
which would enable early detection of PrEP failures and
prompt initiation of treatment.
Based on our findings we would assume that continu-
ing and increasing test promotion for MSM will increase
the use of serostatus disclosure for HIV risk manage-
ment, particularly within steady partnerships and with
other partners with whom men have AI repeatedly or on
a regular basis. This should be tested and confirmed by
future research. Assuming that (consistent) condom use
is less prone to unintended HIV exposures than HIV ser-
osorting, future increases or declines of HIV transmis-
sion risks amongst MSM will thus partly depend on the
strategies that they replace: risks may decline if no dis-
cernible risk management has previously been used,
risks may increase if current condom users increasingly
adopt serosorting instead.
To reach the goal of ending HIV/AIDS as a public
health emergency amongst MSM in Europe by 2030,
likely a combination of different approaches and strat-
egies will be required: maintaining or improving consist-
ent condom use for AI; early and effective ART after
HIV diagnosis; increased HIV testing frequency to im-
prove the accuracy of HIV serostatus awareness; in-
creased mutual HIV serostatus disclosure and serostatus
knowledge particularly within steady partnerships; the
provision and correct use of oral HIV chemoprophylaxis
(PrEP) for men engaging frequently in CLAI with known
and untreated HIV-serodiscordant partners or with non-
steady partners.
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